Table V.
Association of the ER status of the primary breast tumor with aberrant PI3KCA signaling and other markers.
| Tumor characteristic | n | P-value (χ2 square or Fisher's exact test) |
|---|---|---|
| PI3KCAα + CTCs vs. ER status | 85 | 0.163 |
| PI3KCA mutation in tumor tissue vs. | 85 | 0.527 |
| ER status | ||
| PTEN loss in tumor tissue vs. | 80 | 0.969 |
| ER status | ||
| PTEN loss and/or PI3KCA mutation | ||
| in tumor tissue vs. ER status | 85 | 0.825 |
| slCTCs and/or CTCs in EMT vs. | 85 | 0.015 |
| ER status | ||
| slCTCs vs. ER status | 85 | 0.425 |
Statistical analysis with contingency tables did not show a significant correlation between the ER status of the primary tumor and aberrant PI3KCA signaling in CTCs or tumor tissue except for the presence of slCTCs and/or CTCs in EMT. ER, estrogen receptor; PI3KCA, phosphatidylinositol 3-kinase; CTCs, circulating tumor cells; PTEN, phosphatase and tensin homolog; slCTCs, stemness-like CTCs; EMT, epithelial-mesenchymal transition; pts, patients.